The <scp>HBP</scp> Pathway Inhibitor <scp>FR054</scp> Enhances Temozolomide Sensitivity in Glioblastoma Cells by Promoting Ferroptosis and Inhibiting O‐<scp>GlcNAcylation</scp>
Our findings demonstrate that targeting the HBP pathway with FR054 can overcome TMZ resistance in GBM by reducing O-GlcNAc modification and inducing ferroptosis. This novel approach enhances the efficacy of TMZ, offering a promising therapeutic strategy for GBM patients with limited treatment options.
Authors
- Guozhong Yi (ORCID: https://orcid.org/0000-0001-5306-4663)
- Rongyang Xu (ORCID: https://orcid.org/0000-0001-8914-4454)
- Shanqiang Qu (ORCID: https://orcid.org/0000-0002-2709-0101)
- Wanghao Zhang
- Zhu Ye
- Huayang Zhang (ORCID: https://orcid.org/0000-0001-5207-8932)
- Xian Zhang (ORCID: https://orcid.org/0000-0001-7023-7351)
- Guanglong Huang (ORCID: https://orcid.org/0000-0002-1589-9202)
- Junyi Xu
- Rongxu Ye
Institutions
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/cns.70546
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Guangdong Science and Technology Department